Riociguat Improves Survival and Reduces Heart and Kidney Damage in Dahl Rats
Author Information
Author(s): Geschka Sandra, Kretschmer Axel, Sharkovska Yuliya, Evgenov Oleg V., Lawrenz Bettina, Hucke Andreas, Hocher Berthold, Stasch Johannes-Peter
Primary Institution: Bayer HealthCare, Wuppertal, Germany
Hypothesis
Does riociguat prevent fibrotic tissue remodeling and improve survival in salt-sensitive Dahl rats?
Conclusion
Riociguat significantly improves survival and reduces tissue remodeling in the heart and kidneys of salt-sensitive Dahl rats.
Supporting Evidence
- Riociguat increased survival from 33% to 85% in treated rats.
- Histological examination showed reduced fibrotic remodeling in heart and kidneys.
- Riociguat treatment significantly lowered levels of pro-fibrotic biomarkers.
Takeaway
This study shows that a drug called riociguat helps sick rats live longer and keeps their hearts and kidneys healthier.
Methodology
Dahl salt-sensitive rats were treated with riociguat for 14 weeks, and various health metrics were measured.
Limitations
The study did not include healthy control rats for baseline comparisons.
Participant Demographics
Male Dahl salt-sensitive rats, aged 8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website